The Nitto Group places ESG (Environmental, Social and Governance) at the core of its management, aiming to simultaneously solve social issues and create economic value. We need to solve climate change, especially global warming, as a common issue for all humankind, to pass on the bountiful planet to future generations.
The new factory at the Tohoku Plant will begin operations to lead the Nitto Group's decarbonization as a CO2 zero emission factory that does not use fossil fuels. Specifically, the solar panels will be doubled to 1,500 KW, and surplus electricity generated on holidays will be used to produce green hydrogen, which will be stored in hydrogen tanks. Steam boilers fueled by hydrogen gas has been introduced in place of conventional steam boilers using fossil fuels. This is the first initiative in Japan to use a large amount of liquefied hydrogen to produce hydrogen gas and operate steam boilers.
The Nitto Group will accelerate its activities to realize a decarbonized society through the use of environmental technology and green energy that make the best use of energy generated.
About the Tohoku Plant
The Tohoku Plant started operation in March 1977 and manufactures oligonucleotide therapeutics related products such as NittoPhase™*2, pharmaceuticals, and medical hygiene materials. The new factory, which was completed in the Tohoku Plant, is the latest factory for oligonucleotide therapeutics related products with the aim of increasing production of NittoPhase™ under the concept of a "sustainable factory friendly to humans and the environment," ensuring high quality and safety while achieving high productivity and providing future expandability. In terms of environmental initiatives, the factory is working to achieve zero CO2 emissions by converting surplus electricity from solar power generation to hydrogen and installing hydrogen boilers. In addition, it is also tackling to reduce the solvent consumption by recycling organic solvents. By increasing the production capacity of NittoPhase™ at the Tohoku Plant, Nitto will support the rapidly growing oligonucleotide therapeutics industry and contribute to people's health and a secure society.
■ Nitto Denko Corporation Tohoku Plant
Reference:
For any inquiries about this press release.
Nitto is present in 14 countries in the EMEA region. Find your local contact details here.